TransCure bioServices secures $2.8 million funding to accelerate global growth and expand its in-vivo preclinical pharmacology services

TransCure bioServices, a preclinical services startup dedicated to in-vivo full human immune system mouse models, has secured $2.8 million (2.5 million euros) funding to widen its range of services and to investigate new exciting areas in the field of full human antibodies. The new capital infusion will enable the company, healthy and profitable for the last three years, to accelerate its international sales growth as well as to expand in vivo preclinical pharmacology services offers into new product lines. In conjunction with the funding, the company also announced that Marc Le Bozec, Managing Director of Arbevel Life Sciences Crossover I Fund, will now join its Supervisory Board.

This financing was entirely led by Arbevel Life Sciences Crossover I, a european private equity fund based in Paris (France) with a cross-over approach. TransCure bioServices will use the proceeds to expand its profitable business activities in Europe and the USA, and to develop additional platforms for international pharmaceutical and biotech companies.

Commenting on the funding, Marc Le Bozec, Managing Director of Arbevel Life Sciences Crossover I Fund, said: “We are excited to collaborate with TransCure bioServices’ management in expediting its growth by addressing new markets and strengthening its commercial team”.

“We welcome Arbevel as a new shareholder to boost our healthy and profitable international CRO business which generated significant growth over the past 3 years. In addition to the ongoing full human immune system mouse models for immuno-oncology, inflammation, and infectious diseases we are excited to develop new hu-liver and 100% human monoclonal antibody services. We look forward to the contribution of Marc Le Bozec in the Supervisory Committee and to benefit from his expertise of preclinical CRO business and financial markets,” Patrick Nef, Chief Executive Officer and co-founder of TransCure bioServices, added.

TransCure bioServices SAS is a European CRO based in France offering pre-clinical in vivo pharmacology fee-for-services to international pharmaceutical, biotech and academic customers. Uniquely designed full human immune system and hu-liver mouse models provide predictive power for drug profiling and smarter drug candidate selection for immuno-oncology, inflammation (IBD, SLE, MS, RA), auto-immune, infectious (HIV), liver diseases, and vaccines. 

“Arbevel’s investment underlines a steppingstone for the growth of our worldwide business,” says Stéphane Legastelois, Chairman of TransCure bioServices. “It allows TransCure bioServices to widen its range of services and to investigate new exciting areas in the field of full human antibodies.”